Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Biomarin Pharmaceutical Inc stake
total: 670
Viking Global Investors BMRN trades
- Total transactions:
- 36
- New positions:
- 4
- Sold out:
- 3
- Added:
- 21
- Reduced:
- 8
- Held since:
- 2021 Q4
- Held for:
- 19 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen holds 7,616,563 Biomarin Pharmaceutical Inc (BMRN) shares with a market value of roughly $435.82M accounting for 1.24% of the overall portfolio. To date, the estimated cost basis is nearly $77.26 for "buy" trades and estimated average "sell" price is $69.74. Viking Global Investors first purchased BMRN in 2016 Q1, initially acquiring 602,116 shares. Ole Andreas Halvorsen later completely sold out the position and invested in Biomarin Pharmaceutical Inc again in 2021 Q4. Since the initial investment in Biomarin Pharmaceutical Inc (BMRN), Viking Global Investors has made 35 more transactions.
When did Ole Andreas Halvorsen buy Biomarin Pharmaceutical Inc (BMRN)?
Ole Andreas Halvorsen first invested in Biomarin Pharmaceutical Inc (BMRN) in 2016 Q1 at the reported quarter-end price of $82.48 per share.
What's the cost basis of Viking Global Investors's BMRN stake?
The estimated cost basis for Biomarin Pharmaceutical Inc (BMRN) stake is around $77.26 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $77.26
- Weighted AVG sell price:
- $69.74
Ole Andreas Halvorsen's historical trades in Biomarin Pharmaceutical Inc
36 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.24%
|
7,616,563
|
$57.22
|
$435,819,735
|
+7.85% (+554,486)
|
+0.09%
|
|
2026 Q1
|
1.12%
|
7,062,077
|
$56.49
|
$398,936,730
|
+16.98% (+1,025,141)
|
+0.16%
|
|
2025 Q4
|
0.95%
|
6,036,936
|
$59.43
|
$358,775,106
|
-27.46% (-2,285,243)
|
-0.35%
|
|
2025 Q3
|
1.17%
|
8,322,179
|
$54.16
|
$450,729,215
|
-32.28% (-3,966,432)
|
-0.62%
|
|
2025 Q2
|
1.95%
|
12,288,611
|
$54.97
|
$675,504,947
|
+13.78% (+1,488,552)
|
+0.24%
|
|
2025 Q1
|
2.43%
|
10,800,059
|
$70.69
|
$763,456,171
|
+2.75% (+289,509)
|
+0.07%
|
|
2024 Q4
|
2.24%
|
10,510,550
|
$65.73
|
$690,858,452
|
+7.76% (+757,257)
|
+0.16%
|
|
2024 Q3
|
2.50%
|
9,753,293
|
$70.29
|
$685,558,965
|
+38.08% (+2,689,729)
|
+0.69%
|
|
2024 Q2
|
2.24%
|
7,063,564
|
$82.33
|
$581,543,224
|
+10.09% (+647,276)
|
+0.2%
|
|
2024 Q1
|
2.09%
|
6,416,288
|
$87.34
|
$560,398,594
|
+31.23% (+1,526,834)
|
+0.5%
|
|
2023 Q4
|
1.73%
|
$96.42
|
+15.99% (+673,998)
|
|||
|
2023 Q3
|
1.51%
|
$88.48
|
+1.41% (+58,671)
|
|||
|
2023 Q2
|
1.48%
|
$86.68
|
+91.68% (+1,988,168)
|
|||
|
2023 Q1
|
0.99%
|
$97.24
|
-58.88% (-3,105,003)
|
|||
|
2022 Q4
|
2.73%
|
$103.49
|
+3.42% (+174,456)
|
|||
|
2022 Q3
|
2.00%
|
$84.77
|
+0.92% (+46,571)
|
|||
|
2022 Q2
|
1.92%
|
$82.87
|
+34.65% (+1,300,200)
|
|||
|
2022 Q1
|
1.17%
|
$77.10
|
+30.75% (+882,446)
|
|||
|
2021 Q4
|
0.73%
|
$88.35
|
new
|
|||
|
2020 Q2
|
0.00%
|
$84.50
|
-100% (-1,453,625)
|
|||
|
2020 Q1
|
0.64%
|
$84.50
|
-10.37% (-168,114)
|
|||
|
2019 Q4
|
0.64%
|
$84.55
|
-46.97% (-1,436,365)
|
|||
|
2019 Q3
|
1.07%
|
$67.40
|
+18.06% (+467,753)
|
|||
|
2019 Q2
|
1.00%
|
$85.65
|
-49.50% (-2,538,558)
|
|||
|
2019 Q1
|
2.61%
|
$88.83
|
+0.73% (+37,272)
|
|||
|
2018 Q4
|
2.47%
|
$85.15
|
+23.32% (+962,696)
|
|||
|
2018 Q3
|
2.22%
|
$96.97
|
+26.66% (+869,184)
|
|||
|
2018 Q2
|
1.76%
|
$94.20
|
+93.75% (+1,577,291)
|
|||
|
2018 Q1
|
0.82%
|
$81.07
|
new
|
|||
|
2017 Q3
|
0.00%
|
$90.82
|
-100% (-259,656)
|
|||
|
2017 Q2
|
0.16%
|
$90.82
|
-70.36% (-616,457)
|
|||
|
2017 Q1
|
0.34%
|
$87.78
|
-37.35% (-522,344)
|
|||
|
2016 Q4
|
0.53%
|
$82.84
|
+185.22% (+908,153)
|
|||
|
2016 Q3
|
0.20%
|
$92.52
|
new
|
|||
|
2016 Q2
|
0.00%
|
$82.48
|
-100% (-602,116)
|
|||
|
2016 Q1
|
0.22%
|
$82.48
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.